SPTX — Seaport Therapeutics, Inc.

SPTXSeaport Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · seaporttx.com

18.13USD+3.61%Mkt Cap: 960.33M USDP/E: —Last update: 2026-05-26

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depressi…

Industry Peers

Biotechnology

VRTX

Vertex Pharmaceuticals Incorporated

Regeneron Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

39.41BUSDP/E 74.0

RVMD

Revolution Medicines, Inc.

Indicators:|

Key Statistics

Company

Market Cap960.33M USD

Enterprise Value—

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-74.88M USD

Revenue/Share—

Last Price18.13 USD

Fiscal Year EndDec 2025

MR Quarter—

Employees58

CountryUS

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B—

EPS (TTM)-1.94

EPS (Forward)—

52W Range

14.8540% of range23.00

52W High23.00 USD

52W Low14.85 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE80.91%

ROA-30.07%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-77.94M USD

CapEx (TTM)356.00K USD

FCF Margin—

FCF Yield-5.29%

Net Debt—

Net Debt/EBITDA—

Balance Sheet

Debt/Equity-0.05

Current Ratio17.46

Quick Ratio17.13

Book Value/Sh—

Cash/Share—

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.53.03M

Float2.89M

Insiders35.39%

Institutions28.64%

Technical

SMA 5016.41 (+10.5%)

SMA 20016.41 (+10.5%)

Beta—

S&P 52W Chg28.31%

Avg Vol (30d)654.24K

Avg Vol (10d)333.89K

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—